Open-Label, Randomized, Fixed-Sequence, Crossover Study to Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects

Trial Profile

Open-Label, Randomized, Fixed-Sequence, Crossover Study to Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Dec 2013

At a glance

  • Drugs Maraviroc (Primary) ; Boceprevir; Telaprevir
  • Indications Hepatitis C; HIV-1 infections
  • Focus Pharmacokinetics
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 18 Sep 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Aug 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 02 Aug 2012 Actual initiation date changed from 1 Jul 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top